Integra Lifesciences (NASDAQ: IART) net income
Integra Lifesciences reported a net loss of $516.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $6.9m. Earnings per share were −$6.74.
Integra Lifesciences's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2023, −62.5%. It reported a loss in 2 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$516.5m | — | −31.6% | −$6.74 |
| 2024 | −$6.9m | −110.3% | −0.4% | −$0.09 |
| 2023 | $67.7m | −62.5% | 4.4% | $0.85 |
| 2022 | $180.6m | +6.8% | 11.6% | $2.18 |
| 2021 | $169.1m | +26.3% | 11.0% | $2.00 |
| 2020 | $133.9m | +166.7% | 9.8% | $1.58 |
| 2019 | $50.2m | −17.4% | 3.3% | $0.59 |
| 2018 | $60.8m | −6.1% | 4.1% | $0.73 |
| 2017 | $64.7m | −13.2% | 5.4% | $0.84 |
| 2016 | $74.6m | — | 7.5% | $1.00 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Integra Lifesciences net income compared with its sector
By net income for its latest fiscal year, Integra Lifesciences ranks 475th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Integra Lifesciences, −31.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 473rd | Immunovant | −$505.6m | — |
| 474th | Denali Therapeutics | −$512.5m | — |
| 475th | Integra Lifesciences | −$516.5m | −31.6% |
| 476th | Avantor | −$530.2m | −8.1% |
| 477th | Evolent Health | −$534.5m | −28.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Integra Lifesciences
- How much did Integra Lifesciences earn in fiscal 2025?
- Integra Lifesciences reported a net loss of $516.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $6.9m.
- What are the earnings per share of Integra Lifesciences?
- They were −$6.74 in fiscal 2025, compared with −$0.09 in fiscal 2024.
- What was the most profitable year for Integra Lifesciences?
- Of its last 10 fiscal years, fiscal 2022, with $180.6m.
- Where does Integra Lifesciences rank in its sector by net income?
- It ranks 475th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Integra Lifesciences come from?
- From the annual report (Form 10-K) that Integra Lifesciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Integra Lifesciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Integra Lifesciences: the Integra Lifesciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.